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Cytokine Regulation of Colony-Stimulating Factor (CSF) Production in Cultured Human Synovial Fibroblasts. 11. Similarities and Differences in the Control of Interleukin-1 Induction of Granulocyte-Macrophage CSF and Granulocyte-CSF Production
By John A. Hamilton, Diana S. Piccoli, Jonathan Cebon, Judith E. Layton, Palaniswami Rathanaswani, Shaun R.
McColl, and Tali Leizer
Synovial fibroblasts are likely t o be a significant source of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte-CSF (G-CSF), which could be crucial t o the pathogenesis of rheumatoid arthritis. Using specific enzyme-linked immunosorbent assays (ELISAs) and Northern analysis, GM-CSF and G-CSF expression were followed in human synovial fibroblast-like cells in response t o a number of agents, either alone or in the presence of an optimal stimulatory concentration of interleukin-1 (IL-1). For both CSFs, interferon? (100 U/mL) did not increase their levels but dramatically suppressed the stimulatory action of IL-1, while basic fibroblast growth factor (lo-* mol/L), although nonstimulatory by itself, potentiated IL-l action. The glucocorticoid, dexamethasone mol/L), inhibited IL-1-stimulated CSF production. However, evidence was obtained for noncoordinated CSF regulation. Cyclooxygenase OLONY-STIMULATING factors (CSFs) regulate the C survival, proliferation, and differentiation of hematopoietic progenitor cells into mature cells.' Two such CSFs are granulocyte-macrophage-CSF (GM-CSF), which mediates the clonal proliferation and differentiation of progenitors into granulocytes and macrophages, and granulocyte-CSF (G-CSF), which generates granulocytes from progenitor cells by similar processes. CSFs can also act on mature hematopoietic cells, suggesting a role in immunity and in inflammatory processes.L3z Both GM-CSF and G-CSF enhance antibody-dependent cyt~toxicity,~ neutrophil oxidative metab~lism,~ and phagocytosis by gran~locytes.~ GM-CSF can also act on monocyte/macrophages, for example, to increase plasminogen activator (PA) activityz.6 and to induce class I1 major histocompatibility complex (MHC) antigen expre~sion.~ Activated synovial fibroblast-like cells have been implicated in the invasive, erosive, and hyperplastic properties of the inflamed synovia of rheumatoid lesions. 8 They have been shown in vitro to be activated by cytokines, such as interleukin-1 (IL-1), to produce a number of putative mediators of inflammation and tissue destruction, such as PAY collagenase,'o IL-6," and prostaglandin E, (PGE,)~" and to stimulate DNA synthesis." Many cytokines have been found in the rheumatoid synovium that could be acting on these cells either individually or in combinat i~n . '~' '~ These include IL-1, tumor necrosis factor a (TNFa), and fibroblast growth factor (FGF).l3,I4
GM-CSFi5 and another uncharacterized CSF16 have been identified in rheumatoid synovial fluids; GM-CSF has also been reported in supernatants of rheumatoid synovial tissue cultures and, due to its ability to elevate monocyte class I1 MHC antigens and urokinase-type PA activity, may be important in the pathogenesis of the di~ease.6.~ The cellular source(s) of GM-CSF in the synovial tissue cultures has not been defined, although we have shown that synovial fibroblast-like cells produce both GM-CSF and G-CSF in inhibitors potentiated the action of IL-1 on GM-CSF synthesis but suppressed G-CSF synthesis, suggesting that endogenous cyclooxygenase products can have opposite effects in modulating the levels of each CSF. Also, the lymphokine, IL-4 (250 pmol/L), slightly inhibited GM-CSF formation in the presence of IL-1 but elevated the G-CSF levels in these cultures without having an effect by itself. Transforming growth factor p (~2 0 ng/mL) did not modulate levels of either CSF. Mesenchymal cell production of both GM-CSF and G-CSF is generally viewed as being under coordinate control; our findings suggest that their synthesis in IL-1-stimulated human synoviocytes can be modulated by a number of agents, in some cases with divergent actions depending on which CSF is examined. o 1992 by The American Society of Hematology.
response to IL-1 and TNFa with synergistic interactions being observed between the cytokines"; human chondrocytes and cartilage tissue also respond to IL-1 and to a combination of IL-1 and TNFa to produce these CSFs.18 It has been proposed that such cytokine action on the synoviocytes and cartilage may be contributing to the GM-CSF levels in the clinical
In this report we tested other combinations of cytokines for their influence on synoviocyte GM-CSF and G-CSF production. We show that interferon y (IFNy) suppresses the GM-CSF and G-CSF formation in human synovial fibroblast-like cells resulting from the action of IL-1 and TNFa. In contrast, FGF, although inactive by itself, potentiates to some extent the actions of IL-1 and TNFa on CSF formation, while IL-4 slightly lowers GM-CSF formation and slightly enhances that of G-CSF in the presence of IL-1.
This latter observation suggests that the two CSFs might not always be produced coordinately, an observation supported by the finding that cyclooxygenase inhibitors lower GM-CSF production but enhance G-CSF levels in response to IL-1.
MATERIALS AND METHODS
Human synovial cell explant cultures were established from nonrheumatoid donors, as previously de~cribed.'~ Passaged cells were functionally and morphologically similar to the synovial fibroblast-like cell^.'^ In experiments, synoviocytes were plated overnight at 5 x lo4 cellsl0.5 mL/well in 48-well plates (Costar, Cambridge, MA) in a-modified minimal essential medium (a-MEM, Commonwealth Serum Laboratories, Parkville, Australia) supplemented with 10% heat-inactivated (at 56°C for 30 minutes) fetal bovine serum (FBS; Flow, Sydney, Australia). After washing with phosphate-buffered saline (PBS), pH 7.4, 50-pL cytokine samples were added to 200 p L a-MEM containing 1% FBS, which had been depleted of plasminogen by lysine-Sepharose chromatography to allow the separate measurement of PA activity.19 Synovial cells were usually incubated for a further 24 hours before supernatants were collected and assayed for GM-CSF and Enzyme-linked immunosorbent assays (ELISAs) for GM-CSF and G-CSF. The amount of GM-CSF in the conditioned media was determined using a modification ("Insight-GM"; MRL, Sydney, Australia) of a previously described sandwich ELISA17." in 96-well microtiter plates. This assay used a purified murine monoclonal antibody (MoAb), LMM 111, and a rabbit antihuman GM-CSF serum (R4, 1.12), color development being with peroxidase using 2,2'-azino-bis(3-ethyl-benzthiazoline)-6-sulfonic acid solution (ABTS; Sigma) substrate. For the measurement of G-CSF, an ELISA that was a modification of a previously described radioimmunoassay was used. This assay used a rabbit anti-G-CSF antibody and a murine anti-G-CSF MoAb (LMM201), color development being with peroxidase using the avidin-biotin enhancing system. The sensitivities of the ELISAs were 0.005 ng/mL for GM-CSF and 0.1 ng/mL for G-CSF, respectively.
Northern blot for CSF messenger RNA (mRNA). Synovial fibroblasts were grown to confluence in 75-cm2 tissue culture flasks and treated as described in the figure legends. The cells were harvested by trypsinization and cytoplasmic RNA was purified by either of two NP-40 methods. In one method (see Fig 3) , cytoplasmic RNA was prepared using the method of Gough.22 Briefly, cell pellets were lysed in 10 mmol/L Tris (pH 7.5), 0.15 mol/L NaCl, 1.5 mmol/L MgCl,, 0.65% NP-40; the cytoplasmic lysate was transferred to 7 mol/L urea, 1% sodium dodecyl sulfate (SDS), 0.35 mol/L NaCl, 10 mmol/L EDTA, 10 mmol/L Tris (pH 7.5) plus phenol/chloroform/isoamylalcohol(50:50:1), followed by vigorous vortexing. For the other method of cytoplasmic RNA preparation" (see Fig 2) , cell pellets were lysed in 0.14 mol/L NaQl.5 mmol/L MgCl,, 10 mmol/L Tris (pH 8.6), 0.5% NP-40, and 1 U / p L of RNAse inhibitor for 5 minutes on ice. The lysates were centrifuged for 2 minutes at 12,OoOg in a microfuge and the supernatant was mixed with 1 vol of proteinase K buffer (0.2 mol/L Tris [pH 7.5],25 mmol/L EDTA, 0.3 mol/L NaCl, and 2% SDS plus 200 kg/mL of proteinase K) and incubated for 30 minutes at 37°C. After three consecutive extractions with phenol, phenol:chloroform, and chloroform, the RNA was precipitated with ethanol on dry ice and resuspended in H,O containing Diethylpyrocarbonate (DEPC). Ten to 20 pg of RNA was electrophoresed on a 1% agarose gel containing 2.2 mol/L formaldehyde and transferred onto Hybond-" nylon membranes. The filter was hybridized overnight at 42°C in a standard hybridization buffer containing 2 x lo6 cpm/mL Synovial cell cultures.
G-CSF.
heat-denatured ["PI-labeled fragments of either GM-CSF or G-CSF cDNA that were labeled by the random primer method.u After hybridization the membranes were washed under stringent conditions, dried at room temperature, and exposed for autoradiography at -70°C. Equal loading and integrity of the cytoplasmic RNA in each lane was confirmed by staining the agarose gels with ethidium bromide. Equal loading was alsoverified by the housekeeping genes, y-actin, or glyceraldehyde 3-phosphate dehydrogenase.
The following were obtained as gifts: recombinant human IL-la (specific activity, 5.7 x lo7 U/mg; 1 U/mL -1 pmol/L) (P. Lomedico, Hoffmann-La Roche, Nutley, NJ) (one unit of IL-1 activity was defined as the amount mediating halfmaximal stimulation in the murine thymocyte comitogenesis assay); recombinant human IL-lP (5 X lo7 U/mg) (Genentech, South San Francisco, CA); recombinant human TNFa (5 x lo7 U/mg) (G.R. Adolf, Boehringer Ingelheim, Sydney, Australia) (one unit of TNF activity was defined as the amount causing 50% cytotoxicity of actinomycin D-treated L929 murine fibroblast monolayer~)'~; recombinant human IFN-y (2.4 X lo6 antiviral U/mg) (E. Hochuli, Hoffmann-La Roche, Basel, Switzerland) or (2 x lo7 U/mg) (Genentech); recombinant human IL-4 (> 400 U/pg) (DNAX, Palo Alto, CA)"; purified recombinant human TGFp 
NY) and Upstate Biotechnology Incorporated (Lake Placid, NY).
The GM-CSF probes used in this study were either from the Genetics Institute (Cambridge, MA) or Biogen (Geneva, Switzerland) while the G-CSF probes came from Genetics Institute or S. Nagata (University of Tokyo, Tokyo, Japan). The GAPDH and y-actin probes were from Walter and Eliza Hall Institute and Dr J. Thibodeau (CHUL Research Centre, QuBbec, Canada), respectively.
Expression of results. Measurements in supernatants are presented as mean values * SEM from triplicate cultures. The significance of differences was assessed using a two-tailed Student's t-test; results were considered not significantly different if P 2 .05.
Reagents.
Probes.
RESULTS
IFNy lowers synoviocyte GM-CSF and G-CSF levels. We used ELISAs to quantitate CSF levels because, as discussed previously," there are limitations t o the bioassays used to identify and quantitate them, including interference from other cytokines. As reported previously," untreated human synovial fibroblast-like cells produce undetectable or extremely low levels of GM-CSF and G-CSF. When IFNy (100 U/mL) was added to these cultures, there was no increase in the amounts of either CSF (see Table 1 GM-CSF and G-CSF expression in cytokine-stimulated synoviocytes. As found previously" and also presented in Table 1 , IL-la and TNFa increased both GM-CSF and G-CSF levels, with more of the latter being produced and with IL-1 yielding a stronger response. IFNy (100 U/mL) suppressed these increases in response to optimal concentrations of the stimulating cytokines. The dose-response curves for the effect of IFNy on the stimulatory action of optimal concentrations of IL-1 are presented in Fig 1A and B. The inhibitory action of IFNy (100 to 1,000 U/mL) on IL-1 action was noted in 18 and 16 other experiments for GM-CSF and G-CSF, respectively, and also found in four other experiments when the effect on the weaker response to TNFa17 was analyzed. The degree of inhibition of GM-CSF formation in response to IG1 was often greater than that found for the inhibition of G-CSF formation. The results were the same if the stimulation was prolonged for 48 hours or if the experiments were conducted in 10% FBS. No CSFs were detected in the cell lysates and the modulation by IFNy could be observed within 6 hours. Our results for GM-CSF differ from those of Alvaro-Gracia et a1,% who recently reported that IFNy (100 U/mL) could inhibit GM-CSF formation by human synoviocytes in response to TNFa but not to IL-1; G-CSF regulation was not examined in that study.
The inhibitory action of IFNy on CSF formation was also mirrored at the mRNA level (Fig 2) . IL-1 increased the levels of both steady-state GM-CSF and G-CSF mRNA transcripts, an observation consistent with the inhibitory action of actinomycin D on CSF formation in these cultures, as reported before.I7 IFNy prevented these increases in steady-state mRNA expression; IFNy by itself did not raise the CSF mRNAs. The data are from a typical experiment, but were confirmed in six others.
Endogenous cyclooxygenase products can regulate GM-CSF and G-CSF levels. Both IL-1 and TNFa can elevate the synthesis of human synoviocyte cyclooxygenase products, such as PGE,, which in turn can modulate the levels in the cultures of certain other products resulting from the action of IL-1 and TNFa?." In Table 2 we show that the cyclooxygenase inhibitor, indomethacin, potentiates GM-CSF formation in response to IL-1 but inhibits G-CSF formation under the same conditions. These observations, in the presence of IL-1, were made in 24 other experiments for GM-CSF and in 12 other experiments when G-CSF levels were monitored. Reversal of these effects by PGE, was consistent with the action of indomethacin being via inhibition of the formation of a cyclooxygenase product. Indomethacin was also active at mol/L. Responses to TNFa were similarly modulated by indomethacin. Similar results were observed using naproxen (lo-' to mol/L) and ketoprofen (lo-' to mol/L) in place of indomethacin. The inhibitory action of IFNy described above was also apparent in the presence of indomethacin indicating that a cyclooxygenase product was not involved in the action of the IFNy (data not shown). In fact, IFNy did not regulate PGE, in the synoviocytes either in the presence (data not shown) or absence of IL-1"; the lack of effect on IL-1-stimulated PGE, formation suggests that IFNy was not (2) IFNy(lOOU/mL); (3)IL-la(100U/mL); (4)IL-lu(100U/mL) + IFNy (100 U/mL). The blots were probed with l*P-labeled GM-CSF cDNA and G-CSF cDNA, respectively. y-Actin mRNA served as a "housekeeping" control.
inhibiting CSF formation (Table 1) by interfering with the action of IL-1 with its receptor.
The lymphokine, IL-4, which often has actions opposite to those of IFNy?*' inhibited IL-1-mediated induction of GM-CSF but potentiated its action on G-CSF formation (Table 3) . These observations were repeated with IL-4 (250 pmol/L) in 25 other experiments for GM-CSF and in 16 others for G-CSF. The degree of inhibition of GM-CSF formation by IL-4 was not as dramatic as that by IFNy (see above). IL-4 did not stimulate GM-CSF or G-CSF formation by itself.
The antiinflammatory glucocorticoid, dexamethasone (lo-' mol/L), reversed the stimulatory action of IL-1 on synoviocyte GM-CSF and G-CSF formation ( Table 4) . This observation was made in a total of seven experiments for GM-CSF induction and 11 for the case of G-CSF. Thus, the action of the steroid is not the same as the nonsteroidal antiinflammatory drugs (Table 2 ) because the steroid suppressed the production of both CSFs.
Effects of IL-4 on synoviocyte CSF levels.
Inhibition of CSF formation by glucocorticoid. Table 1 , were incubated for 24 hours with IL-4 (250 pmol/L), IL-la (100 U/mL), or their comblnation, and supernatant GM-CSF and G-CSF measured by immunoassay. Values are means f SEM. ' P < .05, when compared with IL-1-treated cultures.
Effects of FGF and TGFB on CSF formation. We have reported previously that a number of cytokines, namely M-CSF (CSF-l), IL-3, IL-2, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and transforming growth factor a (TGFa), did not stimulate GM-CSF or G-CSF formation either alone or in the presence of an optimal concentration of IL-1 or TNFa.I7 We now demonstrate that basic FGF (lo-* mol/L), although inactive by itself, could potentiate to some extent the stimulatory effect of optimal IL-1 ( Table 5) . Similar findings were also made in 21 other experiments for GM-CSF and 18 others for G-CSF. The enhancement due to FGF could be measured at 6 hours for both CSFs (data not shown). Northern analysis (Fig 3) illustrates that the changes in antigen levels due to FGF were paralleled at the mRNA level.
TGFP (0.02 to 20 ng/mL), which we have reported to stimulate urokinase-type PA activity in the synovial fibroblasts,= failed in several experiments to regulate CSF formation in the absence or presence of an optimal IL-1 concentration (data not shown).
DISCUSSION
We have previously shown that both IL-1 and TNFu stimulate GM-CSF and G-CSF formation in human synoviocytes with the former cytokine being more potent in terms of the degree of enhancement of CSF formation and also of the concentration at which it was active.17 It was concluded that synovial fibroblast-like cells may be a source of GM-CSF" and other as yet uncharacterized CSFs present in rheumatoid synovial fluid.16 The GM-CSF present in these fluids is considered to be important in the maintenance of such lesions because, for example, it can induce class I1 WN, passage 7) . cultured as in Table 1 MHC expression on monocytes7 and the expression of the serine proteinase, PA! In vitro, GM-CSF enhances monocyte adherence to the endothelium,B which could account for the very rapid and transient monocytopenia in evidence after intravenous injection into patients." This enhanced monocyte-endothelial adhesion by locally produced GM-CSF may also be involved in the close apposition of monocytes to the blood vessel wall and in the altered transendothelial migration and intrasynovial accumulation of monocytes into rheumatoid joints:w Furthermore, it has been reported that GM-CSF, when administered to a patient with Felty's syndrome, caused a flare-up of the rheumatoid arthritis in the affected joints.." Synoviocyte G-CSF may also contribute by activating the neutrophils that are present in the synovial fluids of such patients? CSF production by cells, such as fibroblasts, endothelial cells, and monocytes,""" must be tightly regulated in vivo to induce rapid changes in leukocyte numbers but also possibly to limit the magnitude of the inflammatory response and prevent tissue damage.)s Most studies involving the actions of cytokines on synoviocytes have analyzed those of individual cytokines. However, given that a number of cytokines have been detected in the rheumatoid syn~vium,".'~ it is likely that they will be acting in concert on joint cells, such as synoviocytes. For example, we have reported before that IL-1 and TNFa can synergize in stimulating in vitro GM-CSF and G-CSF formation by human synoviocytes" and chondrocytes.lH In the present report we have shown that IFNy suppresses IL-1-induced (and TNFa-induced) GM-CSF and G-CSF production, and concomitantly alters steady-state mRNA levels. Others have recently reportedz6 that IFNy inhibited GM-CSF production induced by TNFa in human synovial fibroblastlike cells, but not that induced by IL-1. The reasons for this discrepancy with regard to the modulation of IL-1 action are unclear as is the mechanism of the inhibitory action of IFNy on CSF gene regulation. It would not appear to involve prostaglandin production nor interference with the interaction of IL-1 with its receptor because IFNy does not modulate PGE, levels of IL-1-treated synoviocytes.lz It is possible that the findings in the present study have clinical significance. Only low levels of IFNy are measurable in synovial eff~si0ns.l~ It could be, therefore, that the reported efficacy of IFNy administration in rheumatoid arthritisM may be due in part to its antagonistic actions on IL-1-and TNFa-mediated CSF production. It has been proposed recently that the combined presence and opposing actions of IFNy and TNFa might be one method by which articular inflammation is normally attenuated.z6 From our prior results" and from results of the present study referred to above, where we found that IL-1 was a more potent stimulus of CSF production than TNFa and that the two cytokines interact synergistically to stimulate CSF production, it could be that the suppression by IFNy of the IL-1 action may be more significant than its previously reported inhibition of TNFa action. 26 We and others have found that, as for GM-CSF and G-CSF formation, IL-1 was more potent than TNFa in stimulating the PGE, and collagenase levels of human synovial fibroblasts and that both cytokines acted synergistically when their combined effects were judged by the same However, when the effects of IFNy have been examined on the cytokine-treated synoviocytes, different results have emerged. IFNy inhibited both IL-1-and TNFa-stimulated collagenase formation in one report, but only the effect of TNFa in
In addition, we have found" no effect of IFNy on IL-1-and TNFa-stimulated PGE, formation, in contrast to the literature?' There have also been discrepancies in the literature when IL-1 and TNFa have been tested for their actions on IFNy-induced class I1 MHC antigen expression on synovial fibroblasts; in human synovial cells, TNFa, but not IL-1, reversed the induction,26 while in rat synovial cells only IL-1 was also effective.'* We also showed that IL-4 could inhibit the GM-CSF production by IL-1-stimulated synoviocytes but stimulate the corresponding G-CSF production. The inhibitory action on GM-CSF formation was generally not as dramatic as that resulting from the presence of IFNy. The differing result with IL-4, depending on which CSF was being examined, illustrates that the two CSFs are not always use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From coordinately regulated (see below). The actions of IFNy and IL-4 on cellular function are sometimes oppositea327; this would seem to apply only for G-CSF formation but not for the case of GM-CSF formation in the stimulated synoviocytes.
The suppressive effect of the cyclooxygenase inhibitors on IL-1-stimulated GM-CSF formation but their potentiation of the corresponding G-CSF levels shows (1) that endogenous cyclooxygenase products can modulate GM-CSF and G-CSF levels, and ( 2 ) that once again that the production of the two CSFs is not always coordinately regulated. In contrast to the nonsteroidal anti-inflammatory drugs, the glucocorticoid, dexamethasone, inhibited the production by IL-1 of both CSFs. This means that the CSFs join the list of products from cytokine-stimulated synoviocytes for which steroids inhibit the action of IL-l,39 including PA,40 collagenase,41 hylauronic and PGE,.43 Such control of CSF formation by this class of steroid may represent a part of their action during the treatment of inflammatory joint disease.
There is evidence for both transcriptional and posttranscriptional control of GM-CSF and G-CSF formation in IL-I-and TNFa-treated connective tissue cells, including human synovial fibroblast-like ce11s. '7,32,34,35 ,44 Also, the data presented so far in the literature suggest that their expression is coordinated in such cytokine-treated ~e l l s .~~-'~ There appears to be some common aspects involved in their regulation in the synoviocytes because (1) IL-1 and TNFa, either alone or in combination with each other,17 and IL-1, in combination with FGF (Table 5 and Fig 3) , raise their levels, and ( 2 ) IFNy (Table 1, Figs 1 and 2) and dexamethasone (Table 4 ) downregulate expression of both CSFs. However, as shown above, there are differences highlighted by the differing responses to cyclooxygenase inhibitors ( Table 2 ) and IL-4 ( Table 3) . The reasons for these similarities and differences in the control of CSF formation will require an analysis of the relevant signaling pathways, including those controlling transcriptional and posttranscriptional events.35."
We showed above that FGF, while being inactive by itself, was able to potentiate the stimulatory action of IL-1 (and also TNFa) on GM-CSF and G-CSF production. It should be mentioned, however, that the potentiating effects of FGF on the actions of IL-1 and TNFa were generally not as dramatic as the interaction between the latter two cytokines,17 these observations also having been made in the same experiment (data not shown). Because FGF, IL-I, and TNFa have been identified in rheumatoid fluid^,^^^'^ these cytokines may be contributing the joint CSF levels via a concerted action on the synoviocytes. TGFP, which elevates urokinase-type PA activity and mRNA transcripts in the synoviocytes, and potentiates the action of IL-1 in this regard,25 did not modulate either CSF expression alone or in the presence of IL-I; therefore, the regulation of urokinase-type PA activity can be dissociated from that of the CSFs. A number of other cytokines, namely M-CSF (CSF-l), IL-3, IL-2, PDGF, EGF, and TGFa, did not stimulate GM-CSF or G-CSF production either alone or in the presence of IL-1," nor did they inhibit the enhancing action of IL-1 (data not shown).
